Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 02 2020
25 02 2020
Historique:
received:
06
09
2019
accepted:
12
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a global health problem. At present, prior exposure to Mtb can be determined by blood-based interferon-gamma release assay (IGRA), but active TB is not always detectable by blood tests such as CRP and ESR. This study was undertaken to investigate whether leucine-rich alpha-2 glycoprotein (LRG), a new inflammatory biomarker, could be used to assess active disease of TB. Cynomolgus macaques pretreated with or without Bacille Calmette-Guerin (BCG) vaccination were inoculated with Mtb to induce active TB. Blood was collected over time from these animals and levels of LRG as well as CRP and ESR were quantified. In the macaques without BCG vaccination, Mtb inoculation caused extensive TB and significantly increased plasma CRP and LRG levels, but not ESR. In the macaques with BCG vaccination, whereas Mtb challenge caused pulmonary TB, only LRG levels were significantly elevated. By immunohistochemical analysis of the lung, LRG was visualized in epithelioid cells and giant cells of the granulation tissue. In humans, serum LRG levels in TB patients were significantly higher than those in healthy controls and declined one month after anti-tubercular therapy. These findings suggest that LRG is a promising biomarker when performed following IGRA for the detection of active TB.
Identifiants
pubmed: 32099022
doi: 10.1038/s41598-020-60450-3
pii: 10.1038/s41598-020-60450-3
pmc: PMC7042324
doi:
Substances chimiques
BCG Vaccine
0
Biomarkers
0
Glycoproteins
0
Interleukin-6
0
LRG1 protein, human
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3384Références
Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J. & Zumla, A. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11, 343–354, https://doi.org/10.1038/nri2960 (2011).
doi: 10.1038/nri2960
pubmed: 21475309
Walzl, G. et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis, https://doi.org/10.1016/S1473-3099(18)30111-7 (2018).
doi: 10.1016/S1473-3099(18)30111-7
Wallis, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect. Dis. 13, 362–372, https://doi.org/10.1016/S1473-3099(13)70034-3 (2013).
doi: 10.1016/S1473-3099(13)70034-3
pubmed: 23531389
Horne, D. J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10, 387–394, https://doi.org/10.1016/S1473-3099(10)70071-2 (2010).
doi: 10.1016/S1473-3099(10)70071-2
pubmed: 20510279
pmcid: 3046810
Dicks, K. V. & Stout, J. E. Molecular Diagnostics for Mycobacterium tuberculosis Infection. Annu. Rev. Med. 70, 77–90, https://doi.org/10.1146/annurev-med-040717-051502 (2019).
doi: 10.1146/annurev-med-040717-051502
pubmed: 30125128
Wallis, R. S. et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 9, 162–172, https://doi.org/10.1016/S1473-3099(09)70042-8 (2009).
doi: 10.1016/S1473-3099(09)70042-8
pubmed: 19246020
Yoon, C. et al. Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis. Int. J. Tuberc. Lung Dis. 21, 1013–1019, https://doi.org/10.5588/ijtld.17.0078 (2017).
doi: 10.5588/ijtld.17.0078
pubmed: 28826451
pmcid: 5633000
Ito, K., Yoshiyama, T., Wada, M. & Ogata, H. C-reactive protein in patients with bacteriological positive lung tuberculosis. Kekkaku 79, 309–311 (2004).
pubmed: 15168438
Serada, S. et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann. Rheum. Dis. 69, 770–774, https://doi.org/10.1136/ard.2009.118919 (2010).
doi: 10.1136/ard.2009.118919
pubmed: 19854709
Shirai, R., Hirano, F., Ohkura, N., Ikeda, K. & Inoue, S. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem. Biophys. Res. Commun. 382, 776–779, https://doi.org/10.1016/j.bbrc.2009.03.104 (2009).
doi: 10.1016/j.bbrc.2009.03.104
pubmed: 19324010
Serada, S. et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm. Bowel Dis. 18, 2169–2179, https://doi.org/10.1002/ibd.22936 (2012).
doi: 10.1002/ibd.22936
pubmed: 22374925
Shinzaki, S. et al. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J. Crohns Colitis 11, 84–91, https://doi.org/10.1093/ecco-jcc/jjw132 (2017).
doi: 10.1093/ecco-jcc/jjw132
pubmed: 27466171
Fujimoto, M. et al. Leucine-rich alpha2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 67, 2056–2060, https://doi.org/10.1002/art.39164 (2015).
doi: 10.1002/art.39164
pubmed: 25917892
Cardona, P. J. & Williams, A. Experimental animal modelling for TB vaccine development. Int. J. Infect. Dis. 56, 268–273, https://doi.org/10.1016/j.ijid.2017.01.030 (2017).
doi: 10.1016/j.ijid.2017.01.030
pubmed: 28163168
Lin, P. L. et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77, 4631–4642, https://doi.org/10.1128/IAI.00592-09 (2009).
doi: 10.1128/IAI.00592-09
pubmed: 19620341
pmcid: 2747916
Zwerling, A. et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 8, e1001012, https://doi.org/10.1371/journal.pmed.1001012 (2011).
doi: 10.1371/journal.pmed.1001012
pubmed: 21445325
pmcid: 3062527
Mori, T. Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J. Infect. Chemother. 15, 143–155, https://doi.org/10.1007/s10156-009-0686-8 (2009).
doi: 10.1007/s10156-009-0686-8
pubmed: 19554399
Mori, M. et al. Analysis of children with tuberculosis in recent 10 years. Kansenshogaku Zasshi 68, 887–893 (1994).
doi: 10.11150/kansenshogakuzasshi1970.68.887
Ha, Y. J. et al. Serum leucine-rich alpha2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still’s disease. Scand. J. Rheumatol. 44, 399–403, https://doi.org/10.3109/03009742.2015.1016103 (2015).
doi: 10.3109/03009742.2015.1016103
pubmed: 26079682
Nakajima, H., Serada, S., Fujimoto, M., Naka, T. & Sano, S. Leucine-rich alpha-2 glycoprotein is an innovative biomarker for psoriasis. J. Dermatol. Sci. 86, 170–174, https://doi.org/10.1016/j.jdermsci.2017.01.008 (2017).
doi: 10.1016/j.jdermsci.2017.01.008
pubmed: 28179066
Shimizu, M., Nakagishi, Y., Inoue, N., Mizuta, M. & Yachie, A. Leucine-rich alpha2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series. Mod. Rheumatol. 27, 833–837, https://doi.org/10.1080/14397595.2016.1270795 (2017).
doi: 10.1080/14397595.2016.1270795
pubmed: 28094589
Kimura, Y. et al. Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis. Sci. Rep. 7, 43732, https://doi.org/10.1038/srep43732 (2017).
doi: 10.1038/srep43732
pubmed: 28262744
pmcid: 5338030
Rainer, T. H. et al. Circulating human leucine-rich alpha-2-glycoprotein 1 mRNA and protein levels to detect acute appendicitis in patients with acute abdominal pain. Clin. Biochem. 50, 485–490, https://doi.org/10.1016/j.clinbiochem.2017.02.010 (2017).
doi: 10.1016/j.clinbiochem.2017.02.010
pubmed: 28202345
Yamamoto, M. et al. Overexpression of leucine-rich alpha2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. Cancer Sci. 108, 2052–2060, https://doi.org/10.1111/cas.13329 (2017).
doi: 10.1111/cas.13329
pubmed: 28746773
pmcid: 5623762
Shinozaki, E. et al. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer 18, 406, https://doi.org/10.1186/s12885-018-4252-6 (2018).
doi: 10.1186/s12885-018-4252-6
pubmed: 29642865
pmcid: 5896117
Watson, C. J. et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ. Heart Fail. 4, 188–197, https://doi.org/10.1161/CIRCHEARTFAILURE.110.952200 (2011).
doi: 10.1161/CIRCHEARTFAILURE.110.952200
pubmed: 21282491
Pek, S. L. et al. Elevation of a novel angiogenic factor, leucine-rich-alpha2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 100, 1586–1593, https://doi.org/10.1210/jc.2014-3855 (2015).
doi: 10.1210/jc.2014-3855
pubmed: 25636050
Liu, J. J. et al. Plasma Leucine-Rich alpha-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus. J. Clin. Endocrinol. Metab. 102, 3683–3691, https://doi.org/10.1210/jc.2017-00930 (2017).
doi: 10.1210/jc.2017-00930
pubmed: 28973352
Hong, Q. et al. LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-beta-Induced Angiogenesis. J. Am. Soc. Nephrol. 30, 546–562, https://doi.org/10.1681/ASN.2018060599 (2019).
doi: 10.1681/ASN.2018060599
pubmed: 30858225
Pek, S. L. T. et al. Association of circulating proinflammatory marker, leucine-rich-alpha2-glycoprotein (LRG1), following metabolic/bariatric surgery. Diabetes Metab. Res. Rev. 34, e3029, https://doi.org/10.1002/dmrr.3029 (2018).
doi: 10.1002/dmrr.3029
pubmed: 29883055
Yasutomi, Y. Establishment of specific pathogen-free macaque colonies in Tsukuba Primate Research Center of Japan for AIDS research. Vaccine 28(Suppl 2), B75–77, https://doi.org/10.1016/j.vaccine.2009.09.079 (2010).
doi: 10.1016/j.vaccine.2009.09.079
pubmed: 20510748